



# Flavonoids isolated from the flowers of *Pulsatilla flavescens* and their anti-piroplasm activity

Dorj Ganchimeg<sup>1,2</sup> · Badarch Batbold<sup>1</sup> · Toshihiro Murata<sup>3</sup> · Bekh-Ochir Davaapurev<sup>1</sup> · Tserendorj Munkhjargal<sup>4,5</sup> · Bumduuren Tuvshintulga<sup>4</sup> · Keisuke Suganuma<sup>4,6</sup> · Ikuo Igarashi<sup>4</sup> · Buyanmandakh Buyankhishig<sup>3</sup> · Kenroh Sasaki<sup>3</sup> · Dulamjav Batsuren<sup>7</sup> · Javzan Batkhuu<sup>1</sup>

Received: 15 January 2019 / Accepted: 21 February 2019  
© The Japanese Society of Pharmacognosy 2019

## Abstract

*Pulsatilla* species are known as “Yargui”, and their flowers are traditionally used in Mongolia as a tonic and for the treatment of inflammatory diseases. By chemical investigation of *P. flavescens* flowers, 21 flavonoids, including a new chalcone C-glucoside, chalconaringenin 2'-O-β-D-glucopyranosyl-5'-β-D-glucopyranoside, and two new flavanone C-glucosides, (2R)- and (2S)-naringenin 8-β-D-glucopyranosyl-4'-O-β-D-glucopyranoside, were isolated. The absolute configurations of the seven flavanone glucosides were elucidated by ECD spectra. For the isolated compounds, inhibitory activity against *Babesia caballi* and *Theileria equi*, which cause fatal diseases in horses, was estimated. Although most of the isolated chalcone and flavanone derivatives did not show any anti-piroplasm activity, all the isolated flavone and flavonol derivatives showed moderate effects against *B. caballi* and/or *T. equi*.

**Keywords** *Pulsatilla flavescens* · Yargui · Flavonoids · Anti-piroplasma activity

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s11418-019-01294-8>) contains supplementary material, which is available to authorized users.

✉ Toshihiro Murata  
murata-t@tohoku-mpu.ac.jp

<sup>1</sup> School of Engineering and Applied Sciences, National University of Mongolia, P.O.B.-617/46A, Ulaanbaatar 14201, Mongolia

<sup>2</sup> School of Natural Science and Technology, Khovd University, Khovd, Khovd Province 84000, Mongolia

<sup>3</sup> Department of Pharmacognosy, Tohoku Medical and Pharmaceutical University, Aoba-ku, Sendai 981-8558, Japan

<sup>4</sup> National Research Center of Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Hokkaido 080-8555, Japan

<sup>5</sup> Institute of Veterinary Medicine, Mongolian University of Life Science, Zaisan, Ulaanbaatar 17042, Mongolia

<sup>6</sup> Research Center for Global Agromedicine, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Hokkaido 080-8555, Japan

<sup>7</sup> Institute of Chemistry and Chemical Technology, Mongolian Academy of Science, Ulaanbaatar 210351, Mongolia

## Introduction

*Pulsatilla* genus plants are called “Yargui” in Mongolia, and their flowers bloom in early spring on the East Asian plateau. The flowers are traditionally welcomed by nomads because are thought of as tonic resources for livestock that have survived the harsh winter. Goats like the flowers, and the meat and blood of goats that have eaten the flowers are thought to produce a healthy life for these nomadic people. *Pulsatilla flavescens* (Zucc.) Juz. (synonym: *Anemone flavescens* Zucc.) is a Ranunculaceae perennial herb commonly called yellow Yargui by the nomadic people. Flowers of *P. flavescens* are used not only as a grass providing a tonic effect for animals but also as a folk medicine for the treatment of infectious diseases, inflammation, and swelling [1]. Ranunculin and its derivative protoanemonin are known to be characteristic contact toxic constituents of *Ranunculus* and *Pulsatilla* plants. It was thought that *P. flavescens* also includes these compounds because of the presence of anemonin, which is a degradation product of the toxic components [2]. Our previous studies focused on the traditional benefits of feeding *P. flavescens* to animals and their toxicity against infectious diseases, including evaluation of the antiprotozoal and antibacterial in vitro activities of the plant

extracts and constituents. *Babesia caballi* and *Theileria equi* infect horses via tick bites and cause equine piroplasmiasis, leading to an increased risk of morbidity and mortality. In Mongolia, an epidemiological survey showed a high rate of *B. caballi* and *T. equi* infections in horse populations [3]. For the Mongolian economy, the livestock sector is very important, with horses, cattle, sheep, goats, and camels being the five main livestock species, all of which can be hosts of piroplasm parasites, with apparent or unapparent infections [4, 5]. In this study, three new flavonoid glucosides and 18 known compounds were isolated from the flowers of *P. flavescens*. The structures of the new compounds were established based on their spectroscopic data, while the absolute configurations of seven flavanone glucosides were elucidated by ECD spectra. To identify anti-piroplasm compounds from this native Mongolian plant, the isolated flavonoids were tested for their anti-piroplasm activities against *B. caballi* and *T. equi*.

## Results and discussion

An acetone–water (3:2) extract of the flowers of *P. flavescens* was dissolved in H<sub>2</sub>O and fractionated with diethyl-ether. The aqueous fraction was applied to an open column using ODS and four fractions were obtained. Further fractionation and purification using preparative HPLC gave 21 flavonoids. The known flavonoids, kaempferol (**1**) [6], apigenin 7-*O*-(6''-*O*-*p*-coumaroyl)- $\beta$ -D-glucopyranoside (**2**) [7], kaempferol 3-*O*-(6''-*O*-*p*-coumaroyl)- $\beta$ -D-glucopyranoside (**3**) [8], kaempferol 7-*O*-(6''-*O*-*p*-coumaroyl)- $\beta$ -D-glucopyranoside (**4**) [9], apigenin 7-*O*-(6''-*O*-*p*-coumaroyl)- $\beta$ -D-glucopyranoside (**5**) [10], apigenin 7-*O*-[6''-*O*-(3'''-hydroxy-3''-methylglutarate)]- $\beta$ -D-glucopyranoside (**6**) [11], quercetin 3-*O*- $\beta$ -D-glucopyranoside (**7**) [12], kaempferol 3-*O*- $\beta$ -D-glucopyranoside (**8**) [12], quercetin 3-*O*-rutinoside (**9**) [12], kaempferol 3-*O*-rutinoside (**10**) [12], kaempferol 3-*O*-[6''-*O*-(*Z*)-*p*-coumaroyl]- $\beta$ -D-glucopyranoside (**11**) [13], quercetin 3-*O*- $\beta$ -D-glucuronopyranoside (**12**) [14], kaempferol 3-*O*- $\beta$ -D-glucuronopyranosyl methyl ester (**13**) [15], (2*R*)- and (2*S*)-naringenin 6,8-di- $\beta$ -D-glucopyranosides (**17**, **18**) [16], (2*R*)- and (2*S*)-isohemipholins (**19**, **20**) [17, 18], and naringenin 7-*O*-[6''-*O*-(*p*-coumaroyl)- $\beta$ -D-glucopyranoside (**21**) [19], were identified based on their spectroscopic values compared with previously published data.

The molecular formula of **14** was determined as C<sub>27</sub>H<sub>32</sub>O<sub>15</sub> based on HR-FAB-MS  $m/z$  597.1818 [M+H]<sup>+</sup> (calcd for C<sub>27</sub>H<sub>33</sub>O<sub>15</sub>, 597.1819). In the aromatic region of the <sup>1</sup>H NMR spectrum of **14** (Table 1), a singlet ( $\delta$  6.28, 1H, s, H-3') and two sets of coupling proton resonances [( $\delta$  7.69, 1H, d,  $J$  = 16.0 Hz, H-7 and 8.02, 1H, d,  $J$  = 16.0, H-8) and ( $\delta$  6.83, 2H, d,  $J$  = 9.0 Hz, H-3 and 5 and 7.61, 2H, d,

$J$  = 9.0 Hz, H-2 and 6)] were observed. Their corresponding carbons were assigned as  $\delta$  95.7 (C-3'), 144.5 (C-7), 125.9 (C-8), 116.9 (C-3 and 5), and 131.9 (C-2 and 6) using the HMQC spectrum. In the HMBC spectrum (Fig. 2), the H-3' resonance was long-range coupled with C-2' ( $\delta$  161.2), C-4' ( $\delta$  164.8), C-5' ( $\delta$  107.0), and C-1' ( $\delta$  107.3), which showed the ring A moiety of a chalcone. Similarly, the HMBC correlations from olefinic proton (H-2) to C-1 ( $\delta$  128.5), C-2, and C-6; from H-2 and H-6 to C-1 and C-4 ( $\delta$  161.4); from H-7 and H-8 to the carbonyl carbon at  $\delta$  194.7 (C-9) were observed, which showed the ring B moiety of the chalcone. Collectively, the above-assigned protons and carbons suggested the presence of a 4,2',4',6'-tetraoxygenated chalcone moiety. The coupling constant between H-7 and H-8 ( $J$  = 16.0 Hz) showed that the C-7 and C-8 double bond is *trans* [20]. Twelve oxygenated sp<sup>3</sup> carbon resonances were observed in the <sup>13</sup>C NMR spectrum, which suggested the presence of two hexose moieties. The anomeric proton at  $\delta$  5.12 (1H, d,  $J$  = 7.0 Hz) and six carbons ( $\delta$  101.9, C-1'''; 75.0, C-2'''; 78.5, C-3'''; 71.8, C-4'''; 78.6, C-5'''; 62.5, C-6''') were assigned as an *O*-glucosyl moiety [12]. Sugar identification using HPLC indicated that the glucosyl moiety was D-glucose, and the coupling constant  $J$  = 7.0 showed its  $\beta$ -orientation. The anomeric proton (H-1''') was HMBC long-range coupled with C-2', showing a 2'-*O*- $\beta$ -D-glucopyranosyl moiety similar to isosalipurposide [20]. For another glycosyl moiety, the anomeric proton at  $\delta$  4.87 (H-1'') and six oxygenated sp<sup>3</sup> carbons ( $\delta$  75.7, C-1''; 72.8, C-2''; 80.2, C-3''; 71.2, C-4''; 82.6, C-5''; 62.8, C-6'') were assigned as a *C*-glucosyl moiety [17]. The anomeric proton (H-1'') had HMBC long-range correlations with C-4', C-5', and C-6', showing the 5'-*C*-glucopyranosyl partial structure. The coupling constant between H-1'' and H-2'' was  $J$  = 9.5 Hz and between H-2'' and H-3'' was  $J$  = 9.0 Hz. Although the configuration was not confirmed by sugar analysis, the NMR data compared with the synthesized flavonoid-*C*- $\beta$ -D-glucoside and the coupling constant suggested that **14** has an 5'-*C*- $\beta$ -D-glucoside moiety [17]. From these data, **14** was determined as chalconaringenin 2'-*O*- $\beta$ -D-glucopyranosyl-5'- $\beta$ -D-glucopyranoside, as shown in Fig. 1.

The molecular formulae of **15** and **16** were determined as C<sub>27</sub>H<sub>32</sub>O<sub>15</sub> based on HR-FAB-MS  $m/z$  597.1810 [M+H]<sup>+</sup> (calcd for C<sub>27</sub>H<sub>33</sub>O<sub>15</sub>, 597.1819) and 619.1631 [M+Na]<sup>+</sup> (calcd for C<sub>27</sub>H<sub>32</sub>O<sub>15</sub>Na, 619.1638), respectively. The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data of **15** and **16** were very close to those of 8-( $\beta$ -D-glucopyranosyl) naringenin (**19** and **20**) except for the presence of additional hexose resonances [**15**:  $\delta$  4.93 (1H, d,  $J$  = 7.5 Hz, H-1''');  $\delta$  102.2 (C-1'''), 74.9 (C-2'''), 78.0 (C-3'''), 71.8 (C-4'''), 78.2 (C-5'''), 62.5 (C-6'''); **16**:  $\delta$  4.93 (1H, d,  $J$  = 7.5 Hz, H-1''');  $\delta$  102.3 (C-1'''), 74.9 (C-2'''), 78.0 (C-3'''), 71.9 (C-4'''), 78.2 (C-5'''), 62.5 (C-6''')]. In the HMBC spectra of **15** and **16**, the anomeric proton

**Table 1** NMR spectroscopic data of compounds **14–16**

Position	<b>14</b>		<b>15</b>		<b>16</b>	
	$\delta_{\text{H}}$ ( <i>J</i> in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ ( <i>J</i> in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ ( <i>J</i> in Hz)	$\delta_{\text{C}}$
1		128.5				
2	7.61, d (9.0)	131.9	5.42, dd (12.5, 3.0)	80.2	5.49, dd (13.0, 3.0)	80.1
3	6.83, d (9.0)	116.9	2.79, dd (17.5, 3.0)	43.9	2.78, dd (17.0, 3.0)	44.3
			3.11, dd (17.5, 12.5)		3.02, dd (17.0, 13.0)	
4		161.4		197.8		198.0
5	6.83, d (9.0)	116.9		164.0		163.3
6	7.61, d (9.0)	131.9	5.98, s	96.4	5.96, s	95.8
7	7.69, d (16.0)	144.5		167.3		167.2
8	8.02, d (16.0)	125.9		106.1		105.7
9		194.7		164.2		164.9
10				103.3		103.6
1'		107.3		134.0		134.4
2'		161.2	7.42, d (9.0)	128.8	7.50, d (9.0)	128.5
3'	6.28, s	95.7	7.13, d (9.0)	117.8	7.14, d (9.0)	117.8
4'		164.8		159.3		159.1
5'		107.0	7.13, d (9.0)	117.8	7.14, d (9.0)	117.8
6'		166.8	7.42, d (9.0)	128.8	7.50, d (9.0)	128.5
1''	4.87 <sup>a</sup>	75.7	4.78, d (9.5)	75.2	4.75, d (10.0)	75.4
2''	4.10, dd (9.5, 9.0)	72.8	4.11, dd (9.5, 9.0)	72.6	4.05, dd (10.0, 8.5)	72.5
3''	3.51, dd (9.0, 8.5)	80.2	3.35–3.48 <sup>a</sup>	80.0	3.35–3.48 <sup>a</sup>	80.0
4''	3.45–3.53 <sup>a</sup>	71.2	3.35–3.48 <sup>a</sup>	71.4	3.35–3.48 <sup>a</sup>	71.4
5''	3.41, m	82.6	3.32 <sup>a</sup>	82.5	3.30 <sup>a</sup>	82.4
6''	3.73, dd (12.0, 5.0)	62.8	3.70 <sup>a</sup>	62.9	3.69 <sup>a</sup>	63.1
	3.85, dd (12.0, 2.0)		3.89, dd (12.0, 2.0)		3.87 <sup>a</sup>	
1'''	5.12, d (7.0)	101.9	4.93, d (7.5)	102.2	4.93, d (7.5)	102.3
2'''	3.56, dd (9.0, 7.0)	75.0	3.35–3.48 <sup>a</sup>	74.9	3.35–3.48 <sup>a</sup>	74.9
3'''	3.45–3.53 <sup>a</sup>	78.6	3.35–3.48 <sup>a</sup>	78.0	3.35–3.48 <sup>a</sup>	78.0
4'''	3.45–3.53 <sup>a</sup>	71.8	3.35–3.48 <sup>a</sup>	71.8	3.35–3.48 <sup>a</sup>	71.9
5'''	3.49 <sup>a</sup>	78.6	3.35 <sup>a</sup>	78.2	3.36 <sup>a</sup>	78.2
6'''	3.74, dd (12.0, 5.0)	62.5	3.70 <sup>a</sup>	62.5	3.69 <sup>a</sup>	62.5
	3.92, dd (12.0, 2.0)		3.85, dd (12.0, 2.0)		3.87 <sup>a</sup>	

<sup>a</sup>Unclear signal pattern due to overlapping signals

(H-1''') was long-range coupled with C-4' (**15**:  $\delta$  159.3; **16**:  $\delta$  159.1); in their differential NOE spectra, the H-1''' resonance also correlated with H-3' and H-5' (**15**:  $\delta$  7.13, 2H, d, *J* = 9.0 Hz; **16**:  $\delta$  7.14, 2H, d, *J* = 9.0 Hz) (Fig. 2). These correlations showed the presence of a 4'-*O*- $\beta$ -D-glucopyranosyl moiety of **15** and **16**, and their molecular structure was determined as naringenin 8- $\beta$ -D-glucopyranosyl-4'-*O*- $\beta$ -D-glucopyranoside.

In the ECD spectrum of **15** (Fig. 3), the positive Cotton effect at 288 nm showed the (2*R*)-absolute configuration of **15** [21]. On the other hand, the negative Cotton effect at 288 nm of **16** showed the (2*S*)-absolute configuration of **16**. Therefore, **15** and **16** were determined as (2*R*)-naringenin 8- $\beta$ -D-glucopyranosyl-4'-*O*- $\beta$ -D-glucopyranoside and (2*S*)-naringenin 8- $\beta$ -D-glucopyranosyl-4'-*O*- $\beta$ -D-glucopyranoside, respectively.

Similarly, the 2*R*-absolute configurations of **17** and **19** were determined using the positive Cotton effect at 290 nm, and the 2*S*-absolute configurations of **18**, **20** and **21** were determined using the negative Cotton effect at 290 nm.

Four different concentrations (1, 10, 50, and 100  $\mu$ g/mL) of all isolated flavonoids were evaluated against in vitro growth of *B. caballi* and *T. equi*, and the half maximal growth inhibitory concentration (IC<sub>50</sub>) values are shown in Table 2. The isolated chalcone and flavanone derivatives including new compounds **14–16** did not show an anti-platelet activity, except for **21**. In addition, all flavone and flavonol derivatives (**1–13**) showed moderate effects against *B. caballi* and/or *T. equi*. Compound **11** had the highest growth inhibitory effect (IC<sub>50</sub> 17.7  $\mu$ M) against *B. caballi*, and the relatively high-activity compounds among those isolated here had a *p*-coumaroyl moiety in their structures.






Fig. 1 Structures of compounds 1–21

Fig. 2 Key HMBC and NOE correlations of compounds 14–16



Previous studies [21] also showed that the galloyl moiety on glycosides was a key structure for anti-piroplasma active compounds. The findings of the previous and present studies

suggested that further investigations of the effect by acyl groups against piroplasm parasites are needed. Each active compound was weak, but Yargui includes over 20 of these

**Fig. 3** ECD spectra of compounds **15** and **16****Table 2** Anti-piroplasma activity of compounds **1–21**

Compound	<i>Babesia caballi</i> IC <sub>50</sub> (μM) <sup>a</sup>	<i>Theileria equi</i> IC <sub>50</sub> (μM) <sup>a</sup>
<b>1</b>	220 ± 0.2	201 ± 0.5
<b>2</b>	18.8 ± 0.3	55.6 ± 0.1
<b>3</b>	91.7 ± 0.2	99.9 ± 0.03
<b>4</b>	26.2 ± 1.0	76.0 ± 0.8
<b>5</b>	57.0 ± 0.4	45.2 ± 0.2
<b>6</b>	165 ± 0.3	130 ± 0.1
<b>7</b>	52.9 ± 0.1	113 ± 0.1
<b>8</b>	135 ± 0.1	222 ± 0.6
<b>9</b>	94.3 ± 0.5	– <sup>b</sup>
<b>10</b>	134 ± 0.03	164 ± 0.5
<b>11</b>	17.7 ± 0.3	139 ± 0.6
<b>12</b>	147 ± 0.3	– <sup>b</sup>
<b>13</b>	144 ± 0.1	– <sup>b</sup>
<b>14</b>	– <sup>b</sup>	– <sup>b</sup>
<b>15</b>	– <sup>b</sup>	– <sup>b</sup>
<b>16</b>	– <sup>b</sup>	– <sup>b</sup>
<b>17</b>	– <sup>b</sup>	– <sup>b</sup>
<b>18</b>	– <sup>b</sup>	– <sup>b</sup>
<b>19</b>	– <sup>b</sup>	– <sup>b</sup>
<b>20</b>	– <sup>b</sup>	– <sup>b</sup>
<b>21</b>	118 ± 0.7	52.7 ± 0.1
Diminazene aceturate	0.03	0.67

10 mg/ml of each compound were diluted with culture medium to give concentrations of 1, 10, 50, and 100 μg/mL

<sup>a</sup>Mean ± SD; the treatment was replicated two times for each concentration

<sup>b</sup>IC<sub>50</sub> > 100 μg/mL

flavonoids as typical constituents. These flower flavonoids could be contributing to prevent piroplasmiasis in herbivores.

## Experimental

### General experimental procedures

Optical rotations, UV, ECD, and IR spectra were measured using a JASCO P-2300 polarimeter (Tokyo, Japan),

a Shimadzu MPS-2450 (Kyoto, Japan), a JASCO J-700 spectropolarimeter, and a PerkinElmer Spectrum One FT-IR spectrometer (Waltham, MA, USA), respectively. <sup>1</sup>H NMR (400 MHz) and <sup>13</sup>C NMR (100 MHz) spectra were recorded using a JEOL JNM-AL400 FT-NMR spectrometer (Tokyo, Japan), and chemical shifts are given as δ values with TMS as an internal standard (measured in methanol-*d*<sub>4</sub>, chloroform-*d*<sub>3</sub>, and pyridine-*d*<sub>5</sub>). HMQC (optimized for <sup>1</sup>J<sub>C-H</sub> = 145 Hz) and HMBC (optimized for <sup>n</sup>J<sub>C-H</sub> = 8 Hz) pulse sequences with a pulsed field gradient. HR-FAB-MS data were obtained using a JEOL JMS700 mass spectrometer, with a glycerol matrix. Preparative and analytical HPLC was performed using a JASCO 2089 with UV detection at 210 nm, using the following columns: Ultra Pack ODS-SM-50C-M (37 × 100 mm; Yamazen, Osaka, Japan), TSKgel ODS-120T (21.5 × 300 mm; Tosoh, Tokyo, Japan), Mightysil RP-18 GP (10 × 250 mm; Kanto Chemical, Tokyo, Japan), Cosmosil 5C<sub>18</sub> AR-II (20 × 250 mm; Nacalai Tesque, Kyoto, Japan) and Develosil C<sub>30</sub>-UG-5 (20 × 250 mm; Nomura Chemical, Aichi, Japan).

### Plant material

Flowers of *P. flavescens* were collected in May 2011 at Selkhiin am, Ullanbaatar, Mongolia and identified by Prof. Ch. Sanchir, Institute of Botany, Mongolian Academy of Sciences. A voucher specimen (No. 20110523) was deposited at the Laboratory of Bioorganic Chemistry and Pharmacognosy, National University of Mongolia.

### Extraction and isolation

Dried flowers of *P. flavescens* (480 g) were extracted with acetone–water (3:2) (5 × 2 L). The dried extract (130 g) was suspended in H<sub>2</sub>O (1.5 L) and fractionated separately with diethylether. The aqueous fraction was concentrated to a blown solid, and subjected to column chromatography (Mitsubishi Diaion HP-20, 500 mL) to yield fraction 1A [1 L MeOH:H<sub>2</sub>O (1:4, v/v), 5.87 g], fraction 1B [1 L MeOH:H<sub>2</sub>O (1:1, v/v), 9.66 g], fraction 1C [1 L MeOH:H<sub>2</sub>O (4:1, v/v), 7.80 g], and fraction 1D (MeOH, 1.22 g). Fraction 1B was loaded onto a reverse-phase ODS-SM-50C-M column, and eluted with MeOH–H<sub>2</sub>O (gradient system from 1:4 to 1:1,

v/v) as the mobile phase to yield fractions 2A–2I. Fraction 2F (317 mg) was subjected to preparative HPLC to isolate compounds **14** (13.8 mg), **19** (4.4 mg), **20** (24.2 mg) [TSK-gel ODS-120T, CH<sub>3</sub>CN–H<sub>2</sub>O (3:17, v/v) containing 0.2% TFA; Develosil C<sub>30</sub>-UG-5, CH<sub>3</sub>CN–H<sub>2</sub>O (3:17, v/v) containing 0.2% TFA] and fraction 2C (317 mg) was subjected to preparative HPLC to obtain compounds **15** (16.9 mg), **16** (4.2 mg), **17** (3.0 mg), and **18** (3.6 mg) [TSK-gel ODS-120T, CH<sub>3</sub>CN–H<sub>2</sub>O (3:17, v/v) containing 0.2% TFA; Develosil C<sub>30</sub>-UG-5, CH<sub>3</sub>CN–H<sub>2</sub>O (3:17, v/v) containing 0.2% TFA]. Fraction 1C (7.8 g) was loaded onto a reverse-phase ODS-SM-50C-M column, and eluted with MeOH–H<sub>2</sub>O (gradient system from 3:2 to 4:1, v/v) as the mobile phase to yield fractions 3A–3Q. Fractions 3H–J (291 mg) was subjected to preparative HPLC to isolate compound **13** (10.6 mg) [TSK-gel ODS-120T, CH<sub>3</sub>CN–H<sub>2</sub>O (1:3, v/v) containing 0.2% TFA; Develosil C<sub>30</sub>-UG-5, CH<sub>3</sub>CN–H<sub>2</sub>O (1:3, v/v) containing 0.2% TFA] and fraction 3L (281 mg) was subjected to preparative HPLC to isolate compound **11** (1.7 mg) [TSK-gel ODS-120T, CH<sub>3</sub>CN–H<sub>2</sub>O (3:7, v/v) containing 0.2% TFA; Develosil C<sub>30</sub>-UG-5, CH<sub>3</sub>CN–H<sub>2</sub>O (3:7, v/v); containing 0.2% TFA]. Fraction 1D (1.2 g) was loaded onto a reverse-phase ODS-SM-50C-M column, and eluted with MeOH–H<sub>2</sub>O (gradient system from 3:2 to 4:1, v/v) as the mobile phase to yield fractions 4A–4J. Fraction 4D (91.3 mg) was subjected to preparative HPLC to isolate compounds **2** (7.4 mg), **3** (5.9 mg), **5** (14.8 mg), and **21** (10.8 mg) [Cosmosil 5C<sub>18</sub> AR-II, CH<sub>3</sub>CN–H<sub>2</sub>O (3:7, v/v)], fraction 4C (167 mg) was subjected to preparative HPLC to obtain compounds **4** (81.5 mg), **7** (9.5 mg), **8** (24.7 mg), **9** (6.2 mg), **10** (9.7 mg), and **12** (10.7 mg) [Cosmosil 5C<sub>18</sub> AR-II, CH<sub>3</sub>CN–H<sub>2</sub>O (3:7, v/v); Develosil C<sub>30</sub>-UG-5, CH<sub>3</sub>CN–H<sub>2</sub>O (3:17, v/v) containing 0.2% TFA], fraction 4B (322 mg) was subjected to preparative HPLC to obtain compounds **1** (3.3 mg) and **6** (13.3 mg) [Mightysil RP-18 GP, CH<sub>3</sub>CN–H<sub>2</sub>O (3:7, v/v)].

**Chalconaringenin 2'-O-β-D-glucopyranosyl-5'-β-D-glucopyranoside (14)** Yellowish, amorphous solid;  $[\alpha]_D^{28} +6.2^\circ$  (c 1.4, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 373 (3.64); ECD (c 0.20, MeOH) nm ([ $\theta$ ]) 215 (–8800); IR  $\nu_{\max}$  (KBr)  $\text{cm}^{-1}$ : 3380, 1607, 1076; <sup>1</sup>H NMR: (CD<sub>3</sub>OD, 400 MHz) Table 1; <sup>13</sup>C NMR: (CD<sub>3</sub>OD, 100 MHz) Table 1; HRFABMS (positive)  $m/z$  597.1818 [M + H]<sup>+</sup> (Calcd for C<sub>27</sub>H<sub>33</sub>O<sub>15</sub>: 597.1819).

**(2R)-Naringenin 8-β-D-glucopyranosyl-4'-O-β-D-glucopyranoside (15)** Colorless, amorphous solid;  $[\alpha]_D^{22} -81^\circ$  (c 0.97, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 292 (4.13), 329 (4.06); ECD (c 0.20, MeOH) nm ([ $\theta$ ]) 217 (–22,900), 288 (25,900), 329 (–2600), 397 (2700); IR  $\nu_{\max}$  (KBr)  $\text{cm}^{-1}$ : 3380, 1648, 1615, 1077; <sup>1</sup>H NMR: (CD<sub>3</sub>OD, 400 MHz) Table 1; <sup>13</sup>C NMR: (CD<sub>3</sub>OD, 100 MHz) Table 1; HRFABMS (positive)  $m/z$  597.1810 [M + H]<sup>+</sup> (Calcd for C<sub>27</sub>H<sub>33</sub>O<sub>15</sub>: 597.1819).

**(2S)-Naringenin 8-β-D-glucopyranosyl-4'-O-β-D-glucopyranoside (16)** Colorless, amorphous solid;  $[\alpha]_D^{22} -150^\circ$  (c 0.38, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 292 (4.18), 326 (4.02); ECD (c 0.20, MeOH) nm ([ $\theta$ ]) 224 (–5600), 252 (5000), 288 (–16,000), 326 (4900), 380 (1600); IR  $\nu_{\max}$  (KBr)  $\text{cm}^{-1}$ : 3394, 1645, 1615, 1078; <sup>1</sup>H NMR: (CD<sub>3</sub>OD, 400 MHz) Table 1; <sup>13</sup>C NMR: (CD<sub>3</sub>OD, 100 MHz) Table 1; HRFABMS (positive)  $m/z$  619.1631 [M + Na]<sup>+</sup> (Calcd for C<sub>27</sub>H<sub>32</sub>O<sub>15</sub>Na: 619.1638).

**Compound 17** Colorless, amorphous solid;  $[\alpha]_D^{22} -101^\circ$  (c 0.33, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 292 (3.92), 334 (4.05); ECD (c 0.17, MeOH) nm ([ $\theta$ ]) 218 (–15,300), 290 (23,000), 331 (–400), 403 (3500).

**Compound 18** Colorless, amorphous solid;  $[\alpha]_D^{22} -84^\circ$  (c 0.40, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 292 (3.91), 334 (4.04); ECD (c 0.20, MeOH) nm ([ $\theta$ ]) 219 (14,000), 240 (–700), 257 (4700), 290 (–8900), 330 (5400).

**Compound 19** Colorless, amorphous solid;  $[\alpha]_D^{22} +27^\circ$  (c 0.22, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 226 (3.69), 291 (3.41), 329 (3.29); ECD (c 0.20, MeOH) nm ([ $\theta$ ]) 217 (–24,400), 290 (26,900), 330 (–3900), 398 (2100).

**Compound 20** Colorless, amorphous solid;  $[\alpha]_D^{22} +14^\circ$  (c 1.67, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 226 (3.68), 291 (3.43), 329 (3.21); ECD (c 0.20, MeOH) nm ([ $\theta$ ]) 218 (20,000), 238 (3400), 251 (5000), 290 (–16,000), 330 (5000).

**Compound 21** Colorless, amorphous solid; UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 211 (4.53), 286 (4.39), 314 (4.29); ECD (c 0.20, MeOH) nm ([ $\theta$ ]) 216 (26,000), 236 (4800), 249 (9400), 290 (–26,000), 337 (6500).

## Sugar identification

Glucosidic moiety identification was carried out in accordance with a previously described method [22]. Compounds **14** (1.0 mg), **15** (2.0 mg), **16** (4.6 mg) were separately hydrolyzed with 7% HCl (1 mL) at 60 °C for 2 h, then the mixtures were subjected to the aqueous sugar fractionation. The concentrated sugar fraction was stirred with L-cysteine methyl ester (3 mg) in pyridine (0.5 mL) at 60 °C, 1 h. Then, *o*-tolyl isothiocyanate (3 μL) was added to each solution (60 °C, 1 h). The reaction mixtures were analyzed by high-performance liquid chromatography (HPLC) (Siseido, Capcel Pak C<sub>18</sub>, 4.6 × 250 mm; CH<sub>3</sub>CN–H<sub>2</sub>O (1:3, v/v) containing 0.2% TFA, 1.0 mL/min; detection at 250 nm). The peaks of authentic L-glucose (*t*R = 15.8 min) and D-glucose (*t*R = 17.0 min) derivatives were used to identify the



*O*-glucosidic moieties in **14–16** as *D*-glucose based on the corresponding retention times of 17.0 min.

### Growth inhibitory effects of compounds against *Babesia* and *Theileria* parasites

The USDA strains of *B. caballi* and *T. equi* were maintained in culture media with horse erythrocytes in an atmosphere of 5% O<sub>2</sub> and 5% CO<sub>2</sub> at 37 °C, as described previously [23]. Culture media (medium 199 used for *T. equi* and RPMI-1640 used for *B. caballi*) were purchased from Sigma-Aldrich (Tokyo, Japan) and prepared with 40% horse serum and 1× antibiotic antimycotic solution containing 100 U/mL penicillin G, 100 µg/mL streptomycin and 0.25 µg/L amphotericin B, as described previously [18]. Horse erythrocytes and serum were obtained from an adult horse at the horse field center of Obihiro University of Agriculture and Veterinary Medicine (Hokkaido, Japan). These parasite cultures were used in further experiments to evaluate the growth inhibitory effects of the isolated compounds. Tests with parasites were performed using a previously described method [23, 24]. Briefly, percent parasitized erythrocytes (PE) were diluted with fresh erythrocytes to afford 1% PE. From this stock, 5 (equine piroplasms) µL of 1% PE were dispensed into a 96-well culture plate (Nunc, Roskilde, Denmark) with 95 µL of culture medium containing four different concentrations of the compounds (1, 10, 50 and 100 µg/mL). Cultures were incubated as described above without changing the medium. On day 4 of culture, 100 µL of lysis buffer with SYBR Green I nucleic acid stain (2×; Lonza, Walkersville, MD, USA; 10,000×) was added and incubated for 8 h in the dark at room temperature. Subsequently, relative fluorescence values were determined using a fluorescence plate reader (Fluoroskan Ascent; Thermo Labsystems, Philadelphia, PA, USA), and the IC<sub>50</sub> values of the compounds against the growths of the parasites were calculated using a curve-fitting method.

**Acknowledgments** We thank Dr. B. Odonbayar, Mr. T. Ishikawa, and Mr. Y. Muraki, Mr. S. Sato, and Mr. T. Matsuki, Tohoku Medical and Pharmaceutical University, for assistance with the compound isolations and the MS measurements. This work was supported by JICA M-JEED project, Grant-in-aid project from Mongolian Foundation of Science and Technology (2018/58), and Grant for Advanced Research at National University of Mongolia (P2018-3601). This work was partially supported by the Kanno Foundation of Japan, a Cooperative Research Grant (29-joint-6, 30-joint-11) from the National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, and AMED/JICA SATREPS.

### Compliance with ethical standards

**Conflicts of interest** The authors indicate that there is no conflict of interest.

## References

- Batkhuu J, Sanchir C, Ligaa U, Jamsran T (2005) Colored illustrations of Mongolian useful plants. Admon Ulaanbaatar 2:191
- <http://www.mabs.jp/archives/pdf/h23report.pdf>
- Munkhjargal T, Sivakumar T, Battsetseg B, Nyamjargal T, Aboulaila M, Purevtseren B, Bayarsaikhan D, Byambaa B, Terkawi MA, Yokoyama N, Igarashi I (2013) Prevalence and genetic diversity of equine piroplasms in Tov province, Mongolia. Infect Genet Evol 16:178–185
- Uilenberg G (2006) Babesia-A historical overview. Vet Parasitol 138:3–10
- Qablan MA, Sloboda M, Jirků M, Oborník M, Dwairi S, Amr ZS, Hořín P, Lukeš J, Modrý D (2012) Quest for the piroplasms in camels: Identification of *Theileria equi* and *Babesia caballi* in Jordanian dromedaries by PCR. Vet Parasitol 186:456–460
- Grienke U, Zöll M, Peintner U, Rollinger JM (2014) European medicinal polypores—a modern view on traditional uses. View on traditional uses. J Ethnopharmacol 154:564–583
- Sadhu SK, Okuyama E, Fujimoto H, Ishibashi M (2003) Separation of *Leucas aspera*, a medicinal plant of bangladesh, guided by prostaglandin inhibitory and antioxidant activities. Chem Pharm Bull 51:595–598
- Wan C, Yuan T, Cirello AL, Seeram NP (2012) Antioxidant and α-glucosidase inhibitory phenolics isolated from highbush blueberry flowers. Food Chem 135:1929–1937
- Kubo I, Yokokawa Y (1992) Two tyrosinase inhibiting flavonol glycosides from *Buddleia coriacea*. Phytochemistry 31:1075–1077
- El-Ansari MA, Nawwar MA, Saleh NAM (1995) Stachysetin, a diapiogenin-7-glucoside-p, p'-dihydroxytruxinate from *Stachys aegyptiaca*. Phytochemistry 40:1543–1548
- Tschan GM, König GM, Wright AD, Sticher O (1996) Chamaemeloside, a new flavonoid glycoside from *Chamaemelum nobile*. Phytochemistry 41:643–646
- Kazuma K, Noda N, Suzuki M (2003) Malonylated flavonol glycosides from the petals of *Clitoria ternatea*. Phytochemistry 62:229–237
- Tsukamoto S, Tomise K, Aburatani M, Onuki H, Hirorta H, Ishiharajima E, Ohta T (2004) Isolation of cytochrome P450 inhibitors from strawberry fruit, *Fragaria ananassa*. J Nat Prod 67:1839–1841
- Kajjout M, Rolando C (2011) Regiospecific synthesis of quercetin *O*-β-D-glucosylated and *O*-β-D-glucuronidated isomers. Tetrahedron 67:4731–4741
- Jung HA, Kim JE, Chung HY, Choi JS (2003) Antioxidant principles of *Nelumbo nucifera* stamens. Arch Pharm Res 26:279–285
- Okamura N, Yagi A, Nishioka I (1981) Studies on the constituents of *Zizyphi Fructus*. V. Structures of glycosides of benzyl alcohol, vomifoliol and naringenin. Chem Pharm Bull 29:3507–3514
- Santos RG, Xavier NM, Bordado JC, Rauter AP (2013) Efficient and first regio- and stereoselective direct *C*-glycosylation of a flavanone catalysed by Pr(OTf)<sub>3</sub> under conventional heating or ultrasound irradiation. Eur J Org Chem 2013:1441–1447
- Kashiha K, Tomooka N, Vaughan DA, Kaga A, Ono Hiroshi, Kameyama M, Yoshida M (2003) Insecticidal composition containing naringenin derivatives. JP 2003137895A
- Rao LJM, Kumari GNK, Rao NSP (1985) Flavonoid glycosides from *Anisomeles ovata*. J Nat Prod 48:150–151
- Zapesochayaya GG, Kurkin VA, Braslavskii VB, Filatova NV (2002) Phenolic compounds of *Salix acutifolia* Bark. Chem Nat Comp 38:314–318
- Badral D, Odonbayar B, Murata T, Munkhjargal T, Tuvshintulga B, Igarashi I, Suganuma K, Inoue N, Brantner AH, Odontuya G, Sasaki K, Batkhuu J (2017) Flavonoid and galloyl glycosides isolated from *Saxifraga spinulosa* and their antioxidative and

- inhibitory activities against species that cause piroplasmosis. *J Nat Prod* 80:2416–2423
22. Tanaka T, Nakashima T, Ueda T, Tomii K, Kouno I (2007) Facile discrimination of aldose enantiomers by reversed-phase HPLC. *Chem Pharm Bull* 55:899–901
  23. Salama AA, AbouLaila M, Terkawi MA, Mousa A, El-Sify A, Allaam M, Zaghawa A, Yokoyama N, Igarashi I (2014) Inhibitory effect of allicin on the growth of *Babesia* and *Theileria equi* parasites. *Parasitol Res* 113:275–283
  24. Rizk MA, El-Sayed SAE, Terkawi MA, Youssef MA, El Said ESES, Elsayed G, El-Khodery S, El-Ashker M, Elsify A, Omar M, Salama A, Yokoyama N, Igarashi I (2015) Optimization of a fluorescence-based assay for large-scale drug screening against *Babesia* and *Theileria* parasites. *PLoS ONE* 10:e0125276

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.